Bio-Rad completes $650M share repurchase program; plans additional authorization in Q3

BIO-RAD LABORATORIES, INC.

Q2-to-date repurchased $207.4M of Class A common stock, 549,863 shares at avg $377.20.
Aggregate repurchases reach the $650M limit authorized by Board in Nov 2017, July 2020, and July 2022.
Management intends to seek Board approval for additional repurchase authority in Q3 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.